DermaXon will be presenting at BIO 2020, NIH Innovation Zone June 8 -12, 2020
Dermaxon receives grant from the National Institute of Neurological Disorders and Stroke
September 2019: DermaXon received a Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pruritus. This award, titled “TOPICAL SELECTIVE T-TYPE BLOCKERS FOR...
DermaXon LLC awarded grant for continued development of DX308 drug candidate for the treatment of Ichthyosis
MiSSOULA, Montana, Nov. 20, 2018 – DermaXon was been awarded a research grant from The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to further research treatment options for Ichthyosis.
Characterization of CYP26B1-selective Inhibitor, DX314, as a Potential Therapeutic for Keratinization Disorders.
Abstract: Inhibition of cytochrome P450 (CYP)-mediated retinoic acid (RA) metabolism by RA metabolism blocking agents (RAMBAs) increases endogenous retinoids and is an alternative to retinoid therapy. Currently available RAMBAs (i.e. liarozole and talarozole) tend to...
Dermaxon receives grant from the National Institute of Neurological Disorders and Stroke
June 2018: DermaXon received a Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pain. This award titled “Topical selective T-type blockers for the...Upcoming Conferences
Upcoming Conferences June, 2020: BIO Digital DermaXon has been selected by the NIH to present its pipeline at BIO digital, Innovation Zone. This virtual gathering of the global biotech industry provides access to key partners via BIO One-on-One Partnering. The...Past Conferences
In the past, we have presented or had posters at conferences all across the country. Learn more about the events we attended.